Source - LSE Regulatory
RNS Number : 6936X
e-Therapeutics plc
07 January 2022



("e-therapeutics" or the "Company")




Oxford, UK, 7 January 2022 - e-therapeutics plc (AIM: ETX), the drug discovery company, announces that on 6 January 2022, Professor Trevor Jones (Non-Executive Chairman of the Company) subscribed for a total of 17,471 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a price of 43.28 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 July 2021 to 31 December 2021 in accordance with the agreement entered into with Professor Jones, previously announced on 5 October 2016, by which Professor Jones agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-therapeutics' ordinary shares. Such new shares are issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid is the average of the closing mid-market price for the five business days prior to the date of issue. 


Following Admission, Professor Jones will be interested in a total of 1,079,478 ordinary shares of 0.1p in the Company, representing approximately 0.21% of the Company's issued share capital.


Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur at 8:00 a.m. on or around 13 January 2022. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.


Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 514,571,069. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.


The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:



Details of the person discharging managerial responsibilities/person closely associated



Trevor Jones


Reason for the notification



Non-Executive Chairman


Initial notification/ Amendment 

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



e-therapeutics plc 





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 0.1 pence


ISIN: GB00B2823H99


Nature of the transaction

Purchase of shares 


Price(s) and volume(s)

17,471 ordinary shares at a price of 43.28 pence per share


Aggregated information

- Aggregated volume

- Price


17,471 ordinary shares

43.28 pence per share

Aggregated value: £7,561.45


Date of the transaction

6 January 2022



Place of the transaction

Outside a trading venue



For further information, please contact:


e-therapeutics plc

Ali Mortazavi, CEO

Laura Roca-Alonso, CBO

Tel: +44 (0)1993 883 125

SP Angel Corporate Finance LLP

Nominated Adviser and Broker

Tel: +44(0)20 3470 0470

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)



About e-therapeutics plc


e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity. 


The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology. 


e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.